|
Emmanuel J. Ajala
|
| Title: |
Biomedical Researcher/Principal Investigator |
| Industry: |
Research |
| Type of Organization: |
Medical Research Facility |
| Major Product/Service: |
Providing pathophysiological investigation of HIV infection, Ebola viruses, and breast cancer; Medical research towards finding a cure for diabetes |
| Expertise: |
With over 20 years experience, Mr. Ajala is responsible for the pathophysiological investigation of HIV infection, breast cancer, and COVID related illnesses. He is actively involved in silencing the COVID-19 pathway through a set of glycoproteins derived from the immune system's dual mitochondrial and endosomal compartments. |
| Geographic Area of Distribution: |
International |
| Affiliations: |
A.A.A.S.; A.C.S. |
| University/Degree: |
B.Sc., Chemistry, Fisk University; M.Sc., Chemistry, Polytechnic University, Brooklyn; Candidate, Ph.D. |
| Hobbies/Sports: |
Playing soccer, badminton, volleyball |
| Work History: |
Previously, Mr. Ajala served as a chemistry lab instructor with Tennessee State University. He was a teaching assistant with Polytechnic University in Brooklyn, and a surgical technician at St. Anthony's Hospital, in Amarillo, Texas. |
| Published Works: |
Articles pending |
| Career Accomplishments: |
Mr. Ajala was instrumental in the deletion of the Ebola virus glycoprotein pathway critical to its glycosylation that triggered cell circle arrest. |
